184 related articles for article (PubMed ID: 36522617)
1. Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease.
Ze Y; Shao F; Feng X; Shen S; Bi Y; Zhu D; Zhang X
BMC Endocr Disord; 2022 Dec; 22(1):319. PubMed ID: 36522617
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
3. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
4. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
5. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
Erem C; Kandemir N; Hacihasanoglu A; Ersöz HO; Ukinc K; Kocak M
Endocrine; 2004 Oct; 25(1):55-60. PubMed ID: 15545707
[TBL] [Abstract][Full Text] [Related]
7. Transient Hypothyroidism after Radioiodine for Graves' Disease: Challenges in Interpreting Thyroid Function Tests.
Sheehan MT; Doi SA
Clin Med Res; 2016 Mar; 14(1):40-5. PubMed ID: 26864507
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
9. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
Vijayakumar V; Ali S; Nishino T; Nusynowitz M
Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
[TBL] [Abstract][Full Text] [Related]
10. Use of cold iodine in patients with Graves' disease: observations from a clinical practice.
Hao ST; Reasner CA; Becker RA
Endocr Pract; 2001; 7(6):438-42. PubMed ID: 11747279
[TBL] [Abstract][Full Text] [Related]
11. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
[TBL] [Abstract][Full Text] [Related]
12. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
14. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
15. Effect of Lugol's solution on
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Clin Exp Med; 2023 Jul; 23(3):825-831. PubMed ID: 35840869
[TBL] [Abstract][Full Text] [Related]
16. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
17. Favorable outcomes of papillary thyroid microcarcinoma concurrent with Graves' disease after radioactive iodine therapy.
Nishihara E; Ito Y; Kudo T; Ito M; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Jun; 68(6):649-654. PubMed ID: 33551434
[TBL] [Abstract][Full Text] [Related]
18. Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.
Lu L; Gao C; Zhang N
Clin Endocrinol (Oxf); 2021 Feb; 94(2):303-309. PubMed ID: 32734611
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Radioactive Iodine Therapy in Childhood Graves’ Disease in Khon Kaen, Thailand.
Getsuwan S; Wiromrat P; Panamonta O; Panamonta M; Paireepinas S
J Med Assoc Thai; 2016 Aug; 99 Suppl 5():S112-9. PubMed ID: 29905996
[TBL] [Abstract][Full Text] [Related]
20. Time to Normalization and Sustainable Normal Serum Thyrotropin Concentrations in Patients with Hyperthyroidism: Comparison of Methimazole and Radioactive Iodine Treatments.
Azizi F; Saadat N; Abdi H; Mehran L; Masoumi S; Takyar MA; Amouzegar A
Endocr Pract; 2022 Nov; 28(11):1140-1145. PubMed ID: 35948251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]